Skip to main content
SpringerLink
Log in

Patients Who Do Not Take Their Osteoporosis Medications: Can We Help Them Become Compliant?

  • Chapter
The Duration and Safety of Osteoporosis Treatment

Abstract

Patients with chronic diseases frequently do not take their medications correctly. People with osteoporosis are no exception. Epidemiologic data show that noncompliance and nonpersistence should be serious concerns for healthcare professionals who treat this disease. Challenges to having patients improve their medication behaviors include complex dosing regimens, perceived and real side effects, cost and uncertainty about the severity of this disease, and the need for medication. We have developed a substantial literature about noncompliance, and many different interventions have been tested, but behavioral changes are minor and usually fleeting. Understanding why patients with osteoporosis refuse to comply with their medication regimens can help healthcare professionals create and test interventions to improve medication behaviors and reduce fractures that can result from noncompliance and nonpersistence with osteoporosis medicines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    *Important References

    **Very important References

References

*Important References

**Very important References

  1. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care. 2003;9(2):155–71.

    PubMed  Google Scholar 

  2. Fan T, Zhang Q, Sen SS. Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database. Clinicoecon Outcomes Res. 2013;5:589–95.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Iversen MD, Vora RR, Servi A, Solomon DH. Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J Geriatr Phys Ther. 2011;34(2):72–81.

    PubMed  PubMed Central  Google Scholar 

  4. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–31.

    Article  PubMed  CAS  Google Scholar 

  5. Solomon DH, Iversen MD, Avorn J, Gleeson T, Brookhart MA, Patrick AR, Rekedal L, Shrank WH, Lii J, Losina E, Katz JN. Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med. 2012;172(6):477–83.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gold DT. Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging. 2011;28(4):249–55.

    Article  PubMed  Google Scholar 

  7. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.

    Article  PubMed  Google Scholar 

  8. *Schousboe JT. Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep. 2013;11(1):21–9. *This is an excellent review of the literature on adherence with osteoporosis medications and highlights social and behavioral factors that influence behavior.

    Article  PubMed  Google Scholar 

  9. Hiligsmann M, Gathon HJ, Bruyère O, Ethgen O, Rabenda V, Reginster JY. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health. 2010;13(4):394–401.

    Article  PubMed  Google Scholar 

  10. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.

    Article  PubMed  CAS  Google Scholar 

  11. *Curtis JR, Cai Q, Wade SW, Stolshek BS, Adams JL, Balasubramanian A, Viswanathan HN, Kallich JD. Osteoporosis medication adherence: physician perceptions vs. patients’ utilization. Bone. 2013;55(1):1–6. *This article examines differences between patient and physician perceptions of adherence to osteoporosis medications.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C, Berger V, Gaudin AF, Cotté FE. Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health. 2010;10:26.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Copher R, Buzinec P, Zarotsky V, Kazis L, Iqbal SU, Macarios D. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Curr Med Res Opin. 2010;26(4):777–85.

    Article  PubMed  CAS  Google Scholar 

  14. Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR medication adherence & persistence special interest group. Osteoporos Int. 2013;24(12):2907–18.

    Article  PubMed  CAS  Google Scholar 

  15. Nielsen D, Ryg J, Nielsen W, Knold B, Nissen N, Brixen K. Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial. Patient Educ Couns. 2010;81(2):155–60.

    Article  PubMed  Google Scholar 

  16. Naseem S, Linton S, Wiles J, Jones G. ‘Keep taking the tablets’: does brief telephone nurse-led intervention improve adherence to osteoporosis therapy? Age Ageing. 2014;43:i15.

    Article  Google Scholar 

  17. Silverman SL, Gold DT. Healthy users, healthy adherers, and healthy behaviors? J Bone Miner Res. 2011;26(4):681–2.

    Article  PubMed  Google Scholar 

  18. Rosenstock IM. Why people use health services. Milbank Mem Fund Q. 1966;44(Spring):94–127.

    Article  PubMed  Google Scholar 

  19. Becker MH, editor. The health belief model and personal health behavior: health education monograph. San Francisco: Society for Public Health Education; 1974.

    Google Scholar 

  20. Rosenstock IM. The health belief model and preventive health behavior. Health Educ Behav. 1974;2(4):354–86.

    Article  Google Scholar 

  21. Becker MH, Radius SM, Rosenstock IM, Drachman RH, Schuberth KC, Teets KC. Compliance with a medical regimen for asthma: a test of the health belief model. Public Health Rep. 1978;93(3):268–77.

    PubMed  PubMed Central  CAS  Google Scholar 

  22. Rosenstock I. Historical origins of the health belief model. Health Educ Behav. 1974;2(4):328–35.

    Article  Google Scholar 

  23. Khdour MR, Hawwa AF, Kidney JC, Smyth BM, McElnay JC. Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD). Eur J Clin Pharmacol. 2012;68(10):1365–73.

    Article  PubMed  Google Scholar 

  24. Theofilou P. Quality of life and mental health in hemodialysis and peritoneal dialysis patients: the role of health beliefs. Int Urol Nephrol. 2012;44(1):245–53.

    Article  PubMed  Google Scholar 

  25. Gherman A, Schnur J, Montgomery G, Sassu R, Veresiu I, David D. How are adherent people more likely to think? A meta-analysis of health beliefs and diabetes self-care. Diabetes Educ. 2011;37(3):392–408.

    Article  PubMed  Google Scholar 

  26. Tanner-Smith EE, Brown TM. Evaluating the health belief model: a critical review of studies predicting mammographic and pap screening. Soc Theory Health. 2010;8(1):95–125.

    Article  Google Scholar 

  27. *McLeod KM, Johnson CS. A systematic review of osteoporosis health beliefs in adult men and women. J Osteoporos. 2011;2011:197454. doi:10.4061/2011/197454. *This is an excellent explanation of ways in which the Health Belief Model is relevant to osteoporosis.

    PubMed  PubMed Central  Google Scholar 

  28. Hsieh C, Novielli KD, Diamond JJ, Cheruva D. Health beliefs and attitudes toward the prevention of osteoporosis in older women. Menopause. 2001;8(5):372–6.

    Article  PubMed  CAS  Google Scholar 

  29. McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin. 2007;23(12):3137–52.

    Article  PubMed  CAS  Google Scholar 

  30. Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone. 1996;18 Suppl 3:185S–9S.

    Article  PubMed  CAS  Google Scholar 

  31. Peng YL, Hu HY, Luo JC, Hou MC, Lin HC, Lee FY. Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. Osteoporos Int. 2014;25(5):1617–23.

    Article  PubMed  CAS  Google Scholar 

  32. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–34.

    Article  PubMed  Google Scholar 

  33. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E, American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2007;22(10):1479–91.

    Article  PubMed  Google Scholar 

  34. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg (Br). 2007;89(3):349–53.

    Article  Google Scholar 

  35. **Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2010;25(11):2267–94. **This task force report provides critical information on atypical subtrochanteric fractures.

    Article  PubMed  Google Scholar 

  36. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, Zhou H, Burchette RJ, Ott SM. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544–50.

    Article  PubMed  Google Scholar 

  37. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137(8):1144–50.

    Article  Google Scholar 

  38. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther. 2006;28(10):1686–94.

    Article  PubMed  CAS  Google Scholar 

  39. Kendler D, Kung AW, Fuleihan G-H, González González JG, Gaines KA, Verbruggen N, Melton ME. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004;48(3):243–51.

    Article  PubMed  CAS  Google Scholar 

  40. Sunyecz J, Gallagher R, MacCosbe P. Persistence with medication in women taking daily versus weekly bisphosphonates for osteoporosis. Female Patient. 2006;31:21–8.

    Google Scholar 

  41. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva alendronate trial in osteoporosis (BALTO). Curr Med Res Opin. 2005;21(12):1895–903.

    Article  PubMed  CAS  Google Scholar 

  42. Keen R, Jodar E, Iolascon G, Kruse HP, Varbanov A, Mann B, Gold DT. European women’s preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin. 2006;22(12):2375–81.

    Article  PubMed  Google Scholar 

  43. Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin. 2006;22(12):2383–91.

    Article  PubMed  CAS  Google Scholar 

  44. Silverman SL, Cramer JA, Sunyecz JA, Sarawate C, Harley C, Blumentals WA, Poston S, Lewiecki EM. Women are more persistent with monthly bisphosphonates therapy compared to weekly bisphosphonates: 12-month results from 2 retrospective databases. J Bone Miner Res. 2007;22 Suppl 1:S454.

    Google Scholar 

  45. Lee S, Glendenning P, Inderjeeth CA. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int. 2011;22(3):741–53.

    Article  PubMed  CAS  Google Scholar 

  46. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E. Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population. Arthritis Care Res (Hoboken). 2012;64(7):1054–60.

    CAS  Google Scholar 

  47. Adachi JD, Hanley DA, Lorraine JK, Yu M. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study. Clin Ther. 2007;29(9):2055–67.

    Article  PubMed  CAS  Google Scholar 

  48. Arden NK, Earl S, Fisher DJ, Cooper C, Carruthers S, Goater M. Persistence with teriparatide in patients with osteoporosis: the UK experience. Osteoporos Int. 2006;17(11):1626–9.

    Article  PubMed  CAS  Google Scholar 

  49. Mulgund M, Beattie KA, Wong AK, Papaioannou A, Adachi JD. Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis. 2009;1(1):5–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  50. Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D, Siddhanti S, DAPS Investigators. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22(6):1725–35.

    Article  PubMed  CAS  Google Scholar 

  51. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, DAPS Investigators. Final results of the DAPS (Denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317–26.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Kendler DL, Macarios D, Lillestol MJ, Moffett A, Satram-Hoang S, Huang J, Kaur P, Tang ET, Wagman RB, Horne R. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the denosumab adherence preference satisfaction study. Menopause. 2014;21(1):25–32.

    Article  PubMed  Google Scholar 

  53. Jachna CM, Forbes-Thompson S. Osteoporosis: health beliefs and barriers to treatment in an assisted living facility. J Gerontol Nurs. 2005;31(1):24–30.

    Article  PubMed  Google Scholar 

  54. Boulware LE, Carson KA, Troll MU, Powe NR, Cooper LA. Perceived susceptibility to chronic kidney disease among high-risk patients seen in primary care practices. J Gen Intern Med. 2009;24(10):1123–9.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Gao X, Nau DP, Rosenbluth SA, Scott V, Woodward C. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care. 2000;12(4):387–98.

    Article  PubMed  CAS  Google Scholar 

  56. Gerend MA, Aiken LS, West SG, Erchull MJ. Beyond medical risk: investigating the psychological factors underlying women’s perceptions of susceptibility to breast cancer, heart disease, and osteoporosis. Health Psychol. 2004;23(3):247–58.

    Article  PubMed  Google Scholar 

  57. Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med. 2008;23(11):1815–21.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int. 2010;21(11):1899–909.

    Article  PubMed  CAS  Google Scholar 

  59. Cline RR, Farley JF, Hansen RA, Schommer JC. Osteoporosis beliefs and antiresorptive medication use. Maturitas. 2005;50(3):196–208.

    Article  PubMed  Google Scholar 

  60. Schousboe JT, Davison ML, Dowd B, Thiede Call K, Johnson P, Kane RL. Predictors of patients’ perceived need for medication to prevent fracture. Med Care. 2011;49(3):273–80.

    Article  PubMed  Google Scholar 

  61. McGuire LC. Remembering what the doctor said: organization and adults’ memory for medical information. Exp Aging Res. 1996;22(4):403–28.

    Article  PubMed  CAS  Google Scholar 

  62. *Neupert SD, Patterson TR, Davis AA, Allaire JC. Age differences in daily predictors of forgetting to take medication: the importance of context and cognition. Exp Aging Res. 2011;37(4):435–48. *This article tests the importance of cognition and busyness in older and younger adults and shows that less busy older adults remember medication more fully.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke University Medical Center, 3003, Durham, NC, 27710, USA

    Deborah T. Gold PhD

Authors
  1. Deborah T. Gold PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah T. Gold PhD .

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center; University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, USA

    Stuart Silverman

  2. Institute of Clinical Research; Department of Medicine, Holbæk, Denmark, University of Southern Denmark, Odense Patient Data Explorative Network; Holbæk Hospital, Odense, Denmark

    Bo Abrahamsen

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gold, D.T. (2016). Patients Who Do Not Take Their Osteoporosis Medications: Can We Help Them Become Compliant?. In: Silverman, S., Abrahamsen, B. (eds) The Duration and Safety of Osteoporosis Treatment. Springer, Cham. https://doi.org/10.1007/978-3-319-23639-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23639-1_17

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23638-4

  • Online ISBN: 978-3-319-23639-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation